RT Journal Article
SR Electronic
T1 Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e021442
DO 10.1136/bmjopen-2017-021442
VO 8
IS 7
A1 Reo Hamaguchi
A1 Takashi Tsuchiya
A1 Go Miyata
A1 Toshihiko Sato
A1 Kenichi Takahashi
A1 Keisuke Ariyoshi
A1 Shunsuke Oyamada
A1 Satoru Iwase
YR 2018
UL http://bmjopen.bmj.com/content/8/7/e021442.abstract
AB Introduction Although adjuvant capecitabine therapy for patients with colorectal cancer after surgery often causes adverse events (AEs), such as diarrhoea, stomatitis, anorexia and hand-foot syndrome (HFS), there are no standard prevention therapies. Cystine and theanine were reported to attenuate some chemotherapy-associated AEs, and are also expected to attenuate the AEs caused by capecitabine treatment. Therefore, our present study aimed to determine the safety and efficacy of cystine/theanine therapy in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery.Methods and analysis A multi-institutional, prospective, randomised, double-blinded, placebo-controlled, phase II trial is being planned. Patients with colorectal cancer treated with capecitabine as an adjuvant chemotherapy will be randomised into either the cystine/theanine group (n=50) or placebo group (n=50). Data will be collected during four courses of capecitabine therapy. The primary endpoint will be incidence rate of diarrhoea of grade 1 or higher in accordance with the Common Terminology Criteria for AEs (CTCAE) v.4.0, Japanese Clinical Oncology Group (JCOG) version. The secondary endpoints are incidence rates of other AEs (CTCAE v.4.0-JCOG), scores of the Japanese version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire module for all patients with cancer (QLQ-C30) and for patients with colorectal cancer (QLQ-CR29), incidence rate of HFS according to the HFS grading scale, protocol adherence, completion rate of four courses of capecitabine therapy and the proportion of completion without delay or dose reduction, time to completion of four courses of capecitabine and total dose of capecitabine. A sample size of 100 patients will be analysed between November 2016 and April 2018.Ethics and dissemination Ethical approval was obtained at all participating institutions. The results of this study will be submitted for publication in international peer-reviewed journals.Trial registration number UMIN000024784; Pre-results.